Ding XC, Fan PP, Xie P, et al. - Researchers focused on the role of chemotherapy in stage II nasopharyngeal carcinoma (NPC) and investigated the toxicity of chemotherapy for these patients in the age of intensity-modulated radiotherapy (IMRT). They examined a total of 169 patients with stage II NPC. Of these patients, they categorized 149 patients who received chemotherapy into the following three groups: neoadjuvant chemotherapy followed by IMRT (NCT) group, concurrent chemotherapy with IMRT (CCRT) group, and neoadjuvant chemotherapy followed by CCRT (NC+CCRT) group. Additionally, IMRT alone was used to treat 20 patients. For the NCT, CCRT, NC+CCRT groups vs the IMRT alone group, the 10-year OS was estimated to be 69.8%, 63.4%, 69.7% vs 72.4%, respectively. Findings are suggestive of the possibility of achieving satisfactory long-term survival outcomes in patients with stage II NPC who received IMRT. No significant increase in survival could be achieved with additional chemotherapy, however, it may cause a remarkable increment in treatment-related acute toxic reactions.